Inactive

THIS IS NOT A REQUEST FOR PROPOSALS (RFP) OR A REQUEST FOR QUOTATIONS (RFQ); IT IS STRICTLY A REQUEST FOR INFORMATION (RFI). NEITHER UNSOLICITED PROPOSALS NOR ANY OTHER KINDS OF OFFERS WILL BE CONSIDE... THIS IS NOT A REQUEST FOR PROPOSALS (RFP) OR A REQUEST FOR QUOTATIONS (RFQ); IT IS STRICTLY A REQUEST FOR INFORMATION (RFI). NEITHER UNSOLICITED PROPOSALS NOR ANY OTHER KINDS OF OFFERS WILL BE CONSIDERED IN RESPONSE TO THIS RFI. NO CONTRACT WILL BE AWARDED PURSUANT TO THIS ANNOUNCEMENT. 1.0 DISCLAIMER: This RFI is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any other kind of offers will be considered in response to this RFI. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. All information received in response to this RFI that is marked Proprietary will be handled accordingly. Responses to the RFI will not be returned. At this time, questions concerning the composition and requirements for a future RFP will not be entertained. This is a summary of the Statement of Work for this requirement. The Wound Infections Department (WID) within the Bacterial Diseases Branch at WRAIR conducts research to defeat combat-related wound infections. WID conducts requirements-driven programmatic research using a multi-disciplinary approach to characterize wound pathogenesis and develop novel antimicrobial countermeasures for wound infections of Service Members. The WID includes the WRAIR X-ray Crystallography Center, which provides structure-based drug design services to WRAIR, DoD labs, industry, and academic collaborators to support the development of therapeutic and prophylactic countermeasures against bacteria, parasites, and viruses. This project would involve the synthesis and testing of compounds against IspC (Dxr) from A. baumannii and K. pneumoniae, intact organisms, infected animals, and cocrystallography of active compounds with the enzyme. The contractor will be responsible for the design, synthesis, and physical characterization of the small molecules to be tested, as well as transportation of the compound to the testing labs. Resources from this contract will support contractor personnel, chemical synthesis, supplies, equipment, travel, shipping, and analytical costs associated with this portion of the project. RESPONSE INSTRUCTIONS: Respondents should provide a Capabilities Statement that addresses the following: Ability to synthesize inhibitor compounds and prodrugs of stated compunds listed above. Ability to synthesized compounds as stated above. Ability to ship all compounds with a certificate of analysis indicating at least 95% purity.